LDL cholesterol is the main cholesterol result used to estimate and manage atherosclerotic cardiovascular disease risk. Atherosclerosis is the slow buildup of cholesterol-rich plaque inside artery walls, which can lead to heart attack, stroke, peripheral artery disease, and other circulation problems. LDL is often called “bad cholesterol,” but the more precise idea is that LDL particles carry cholesterol into the bloodstream, and too much LDL exposure over time increases plaque formation.
A standard LDL cholesterol test is usually part of a lipid panel, along with total cholesterol, HDL cholesterol, and triglycerides. Many lab reports mark LDL below 100 mg/dL as optimal, but the healthiest target depends on personal risk. Someone with no major risk factors may only need LDL below 100 mg/dL, while someone with established heart disease, diabetes with high risk, familial hypercholesterolemia, or prior heart attack may need a much lower target.
- LDL below 100 mg/dL is commonly considered optimal for many adults without known cardiovascular disease.
- LDL 130–159 mg/dL is borderline high, 160–189 mg/dL is high, and 190 mg/dL or higher is very high.
- People at high cardiovascular risk often need LDL below 70 mg/dL, not merely inside the general lab reference range.
- Very high-risk patients may have an LDL target below 55 mg/dL, especially after heart attack, stroke, or established atherosclerotic disease.
- Fasting is not always required, but fasting may be requested when triglycerides are high or when a more precise calculated LDL is needed.
- A high LDL result is not an emergency by itself, but chest pain, shortness of breath, weakness on one side, or stroke-like symptoms need urgent care.
Table of Contents
- What LDL Cholesterol Measures
- Normal Reference Values and Optimal Ranges
- LDL Targets by Cardiovascular Risk
- How the Test Is Done and How to Prepare
- Causes of High or Low LDL
- How to Interpret Your Result
- Ways to Lower LDL and When to Follow Up
- Related Markers That Refine Risk
What LDL Cholesterol Measures
LDL cholesterol, often written as LDL-C, measures the amount of cholesterol carried inside low-density lipoprotein particles in the blood. Cholesterol itself is not harmful in the right amount. The body uses it to build cell membranes, make steroid hormones, produce bile acids, and support normal nerve function. The problem begins when too many LDL particles circulate for too long, especially in people with other artery-damaging risks such as smoking, high blood pressure, diabetes, chronic kidney disease, or inflammation.
LDL particles can enter the inner lining of arteries. Once trapped there, they may become modified and trigger an immune response. Over years, this process can form atherosclerotic plaque. Plaque can slowly narrow an artery, but the larger danger is plaque rupture. A ruptured plaque can cause a sudden clot, blocking blood flow to the heart or brain.
Most people see LDL as one number on a standard lipid panel. The result may be calculated from total cholesterol, HDL cholesterol, and triglycerides, or it may be measured directly. Many routine lipid panels calculate LDL because it is inexpensive and accurate enough for most people when triglycerides are not very high.
LDL cholesterol is different from LDL particle number. LDL-C tells how much cholesterol is inside LDL particles. LDL particle number, LDL-P, estimates how many LDL particles are present. These two results often move together, but they can disagree in people with insulin resistance, obesity, type 2 diabetes, high triglycerides, or metabolic syndrome. In those cases, someone may have a “reasonable” LDL-C but still carry too many atherogenic particles.
LDL is also different from HDL cholesterol. HDL particles help move cholesterol through reverse cholesterol transport and are often linked with lower cardiovascular risk, but HDL does not cancel out a high LDL level. A person with high HDL can still have plaque risk if LDL, ApoB, non-HDL cholesterol, blood pressure, glucose, or smoking risk is high.
Normal Reference Values and Optimal Ranges
Most lab reports classify LDL cholesterol using population-based categories. These categories help flag results, but they are not the same as treatment targets for every person. A lab may label LDL below 100 mg/dL as “normal,” while a cardiologist may want LDL below 70 mg/dL or below 55 mg/dL in someone with established atherosclerotic disease.
A common LDL cholesterol reference table looks like this:
| LDL-C level | mmol/L equivalent | Common category | General meaning |
|---|---|---|---|
| Less than 70 mg/dL | Less than 1.8 mmol/L | Very low / intensive target range | Often used as a goal for high-risk patients |
| Less than 100 mg/dL | Less than 2.6 mmol/L | Optimal | Desirable for many adults without known heart disease |
| 100–129 mg/dL | 2.6–3.3 mmol/L | Near optimal or above optimal | May be acceptable in low-risk adults but too high for higher-risk adults |
| 130–159 mg/dL | 3.4–4.1 mmol/L | Borderline high | Often prompts risk review and lifestyle treatment |
| 160–189 mg/dL | 4.1–4.9 mmol/L | High | Raises concern for long-term plaque risk, especially with other risk factors |
| 190 mg/dL or higher | 4.9 mmol/L or higher | Very high | Suggests severe hypercholesterolemia and possible familial hypercholesterolemia |
To convert LDL-C from mg/dL to mmol/L, multiply by 0.02586. To convert mmol/L to mg/dL, multiply by 38.67. For example, LDL 100 mg/dL is about 2.6 mmol/L, LDL 70 mg/dL is about 1.8 mmol/L, and LDL 55 mg/dL is about 1.4 mmol/L.
An “optimal” LDL result is best interpreted in context. A healthy 28-year-old nonsmoker with normal blood pressure and LDL 105 mg/dL may receive lifestyle advice and routine follow-up. A 62-year-old with diabetes, kidney disease, and a coronary calcium score showing plaque may need a much lower LDL, even if the lab report does not mark 105 mg/dL as severely abnormal.
LDL categories also do not show lifetime exposure. LDL 150 mg/dL for one month is not the same as LDL 150 mg/dL for 30 years. Long-term exposure matters because plaque risk builds over time. This is why clinicians pay close attention to young adults with LDL 160 mg/dL or higher, even when their short-term 10-year risk score looks low.
LDL Targets by Cardiovascular Risk
LDL targets are lower when cardiovascular risk is higher. The same LDL result can mean different things for different people because treatment is based on total risk, not the LDL number alone.
Risk assessment usually considers age, sex, blood pressure, smoking, diabetes, kidney disease, prior cardiovascular events, family history, inflammatory disease, premature menopause, pregnancy-related complications, coronary artery calcium, and related blood markers. In adults without known atherosclerotic disease, clinicians often estimate 10-year and sometimes 30-year cardiovascular risk before deciding whether lifestyle alone is enough or whether medication should be considered.
| Risk group | Common LDL-C target | Examples of people in this group |
|---|---|---|
| Low risk | Often less than 100–116 mg/dL | No known ASCVD, low estimated risk, no major risk enhancers |
| Borderline or intermediate primary prevention risk | Often less than 100 mg/dL if medication is used | Adults with mild-to-moderate estimated risk or risk enhancers |
| High primary prevention risk | Often less than 70 mg/dL, with a large percentage reduction | High estimated risk, diabetes with multiple risk factors, significant coronary calcium, chronic kidney disease, or several risk enhancers |
| Severe hypercholesterolemia | Often less than 100 mg/dL, or lower if other risks are present | Untreated LDL-C 190 mg/dL or higher, possible inherited cholesterol disorder |
| Established ASCVD | Often less than 70 mg/dL; less than 55 mg/dL for very high risk | Prior heart attack, stroke, coronary stent, peripheral artery disease, or plaque disease |
| Very high-risk ASCVD | Less than 55 mg/dL is commonly used | Recent heart attack, recurrent events, ASCVD plus diabetes, ASCVD plus kidney disease, or multiple high-risk conditions |
These targets are not meant to replace medical judgment. They help guide the conversation. For example, a person with LDL 145 mg/dL, normal blood pressure, no diabetes, and low coronary calcium may receive a different plan than a person with LDL 145 mg/dL plus diabetes, high blood pressure, a strong family history, and elevated lipoprotein(a).
LDL 190 mg/dL or higher deserves special attention. At that level, clinicians usually look for familial hypercholesterolemia, an inherited condition that can expose arteries to high LDL from childhood. People with suspected familial hypercholesterolemia often need earlier and stronger LDL-lowering treatment, and close relatives may need screening.
For people who already have plaque disease, LDL is treated more aggressively because the goal is secondary prevention: preventing another event. A patient who had a heart attack should not compare their LDL target with that of a healthy person having a routine checkup. The artery biology and risk level are different.
How the Test Is Done and How to Prepare
The LDL cholesterol test is a blood test. It is usually ordered as part of a lipid panel, which includes total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Some reports also include non-HDL cholesterol, VLDL cholesterol, total cholesterol/HDL ratio, or LDL/HDL ratio.
Many adults can have a nonfasting lipid panel. Nonfasting testing is convenient and often reflects typical daily metabolism. A fasting sample may be preferred when triglycerides are high, when a previous nonfasting result was abnormal, when the clinician suspects a genetic lipid disorder, or when the laboratory needs the most accurate calculated LDL value.
Fasting usually means no calories for 8–12 hours before the blood draw. Water is allowed. Plain black coffee may be allowed by some clinicians, but instructions vary. Alcohol should usually be avoided for at least 24 hours before testing because it can raise triglycerides and make some lipid results harder to interpret. A very high-fat meal shortly before a nonfasting test can also affect triglycerides.
LDL can be reported in several ways:
- Calculated LDL-C: Estimated from total cholesterol, HDL cholesterol, and triglycerides. This is the most common method.
- Direct LDL-C: Measured by a laboratory assay rather than calculated. It may be used when triglycerides are high or calculation is unreliable.
- More advanced LDL estimates: Some laboratories use newer equations that improve accuracy when LDL is low or triglycerides are moderately elevated.
The older Friedewald calculation becomes unreliable when triglycerides are very high, especially at 400 mg/dL or higher. Even below that level, some equations are less accurate when LDL is very low or triglycerides are elevated. This is one reason clinicians may look at non-HDL cholesterol or ApoB when triglycerides are high.
Testing should not be done during a short-term illness unless there is a specific reason. Acute infection, surgery, trauma, heart attack, major inflammation, or sudden weight loss can temporarily change cholesterol levels. Pregnancy also changes lipid values, often raising LDL and triglycerides. After pregnancy, breastfeeding, major illness, or a medication change, clinicians may repeat testing when the body is back to a stable baseline.
For routine screening, many adults have lipid testing every 4–6 years when risk is low, and more often when results are abnormal or risk factors are present. After starting or changing LDL-lowering treatment, a repeat lipid panel is commonly checked after about 4–12 weeks, then every 3–12 months depending on risk, response, and adherence.
Causes of High or Low LDL
High LDL can come from genetics, lifestyle, medical conditions, medications, or several factors together. It is rarely useful to blame one food or one habit without looking at the full pattern.
A diet high in saturated fat can raise LDL in many people. Common sources include butter, cream, cheese, fatty cuts of meat, processed meats, coconut oil, palm oil, pastries, and many fried or packaged foods. Trans fats, now restricted in many places, can raise LDL and lower HDL. Excess calories and weight gain can also worsen lipid patterns, especially when paired with high triglycerides and insulin resistance.
Genetics strongly affects LDL. Some people eat a generally healthy diet and still have high LDL because their liver clears LDL particles slowly. Familial hypercholesterolemia is the clearest example. Adults with untreated LDL around 190 mg/dL or higher, tendon xanthomas, premature heart disease, or a family history of very high cholesterol may need evaluation for this condition.
Several medical conditions can raise LDL, including:
- Hypothyroidism
- Nephrotic syndrome or significant kidney disease
- Cholestatic liver disease
- Type 2 diabetes and insulin resistance
- Obesity, especially with increased waist size
- Polycystic ovary syndrome
- Chronic inflammatory diseases
- Menopause-related metabolic changes
Medication effects also matter. Some corticosteroids, cyclosporine, certain diuretics, some beta blockers, oral retinoids, some antiretroviral drugs, and certain hormone therapies can worsen cholesterol in susceptible people. Medication should not be stopped without medical guidance, but it is worth reviewing the list when LDL rises unexpectedly.
Low LDL is often intentional, especially in people taking statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, or combination therapy. Low LDL from treatment is usually not a problem by itself when monitored by a clinician. Very low untreated LDL, especially with symptoms, may point to hyperthyroidism, malabsorption, undernutrition, chronic illness, liver disease, or rare genetic conditions.
A sudden LDL change deserves a practical review. Lab variation exists, but a large jump may reflect weight change, diet change, menopause, thyroid disease, kidney protein loss, new medication, pregnancy, or a nonfasting sample with high triglycerides. Repeating the test under stable conditions often helps.
How to Interpret Your Result
Start with the LDL number, then place it next to the rest of the lipid panel and your cardiovascular risk. LDL is important, but it is not the only marker that shapes risk.
A result below 100 mg/dL is generally favorable for many adults without known atherosclerotic disease. If you have heart disease, diabetes with additional risk factors, chronic kidney disease, a high coronary calcium score, or prior stroke, that same value may still be above your target. For high-risk people, “normal” on the lab report may not mean “low enough.”
LDL 100–129 mg/dL is often described as near optimal. In a low-risk adult, it may lead to lifestyle reinforcement rather than medication. In someone with multiple risks, it may lead to a more serious conversation about lowering LDL further.
LDL 130–159 mg/dL is borderline high. This range often calls for a closer look at blood pressure, smoking, glucose, family history, body weight, waist size, exercise, and inflammatory conditions. If triglycerides are also high or HDL is low, the pattern may suggest insulin resistance or metabolic syndrome.
LDL 160–189 mg/dL is high. Even in younger adults, this range may represent a meaningful lifetime exposure to LDL. A young person with LDL 170 mg/dL may have a low 10-year risk score simply because age weighs heavily in risk calculators, but decades of exposure can still matter.
LDL 190 mg/dL or higher is very high. This level usually needs prompt follow-up, repeat confirmation if needed, evaluation for secondary causes, and discussion of inherited cholesterol disorders. Lifestyle changes help, but medication is commonly needed because diet alone often does not lower LDL enough from this range.
LDL interpretation also changes when triglycerides are high. For example, a person with LDL 95 mg/dL and triglycerides 260 mg/dL may still have too many atherogenic particles. Non-HDL cholesterol and ApoB become especially helpful in this setting. A dedicated ApoB test can show whether the number of plaque-forming particles remains high even when LDL-C looks acceptable.
Symptoms do not reliably track LDL. Most people with high LDL feel completely normal. Chest pain, shortness of breath, jaw or arm pain, sudden weakness, facial drooping, trouble speaking, or sudden vision loss are not “cholesterol symptoms”; they may be heart attack or stroke warning signs and need emergency care.
Ways to Lower LDL and When to Follow Up
LDL can be lowered through nutrition, weight management, physical activity, tobacco avoidance, better sleep, and medication when needed. The right plan depends on the starting LDL, target LDL, overall risk, personal preferences, medication tolerance, and other health conditions.
Diet changes can make a meaningful difference. Replacing saturated fat with unsaturated fat is one of the most reliable food-based ways to lower LDL. Practical swaps include olive oil instead of butter, nuts instead of processed snacks, fish instead of fatty processed meats, and low-fat or unsweetened yogurt instead of cream-heavy foods.
Soluble fiber helps lower LDL by binding bile acids in the gut. Oats, barley, beans, lentils, chickpeas, apples, citrus fruits, chia seeds, flaxseed, and psyllium are useful sources. Many people can lower LDL modestly by adding 5–10 grams of soluble fiber per day. Plant sterols and stanols can also reduce LDL when used consistently, often through fortified foods or supplements.
A Mediterranean-style pattern works well for many adults because it emphasizes vegetables, legumes, fruit, whole grains, fish, nuts, seeds, and olive oil while limiting processed meats, refined starches, and sweets. A portfolio-style cholesterol-lowering diet adds several LDL-lowering foods at once, such as soluble fiber, plant sterols, soy protein, and nuts.
Weight loss can improve LDL for some people, but its strongest effects may appear in triglycerides, HDL, glucose, blood pressure, and liver fat. Physical activity may not lower LDL as dramatically as medication, but it improves overall cardiovascular health and helps reduce insulin resistance. A realistic target is at least 150 minutes per week of moderate aerobic activity plus two sessions of resistance training, adjusted for fitness and medical status.
Medication is often appropriate when LDL is very high or cardiovascular risk is high. Statins remain the foundation because they lower LDL and reduce cardiovascular events. Depending on the person’s risk and LDL response, clinicians may add ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies, inclisiran, or other therapies. People with familial hypercholesterolemia or very high-risk ASCVD often need combination therapy.
Follow-up testing shows whether the plan is working. A repeat lipid panel after 4–12 weeks can confirm the LDL response after a medication change or major lifestyle intervention. Once LDL is at target and stable, testing may become less frequent. People with very high risk, medication changes, adherence concerns, or side effects may need closer monitoring.
Follow-up is especially important when LDL is 190 mg/dL or higher, when LDL remains above target despite treatment, when there is premature heart disease in the family, or when other markers such as lipoprotein(a) are high. In those cases, a clinician may recommend more intensive risk assessment or referral to a lipid specialist.
Related Markers That Refine Risk
LDL cholesterol is central, but it is not the whole lipid story. Several related markers can clarify risk when LDL does not match the clinical picture.
Non-HDL cholesterol equals total cholesterol minus HDL cholesterol. It includes cholesterol carried by LDL, VLDL, IDL, remnant particles, and lipoprotein(a). Non-HDL cholesterol is especially useful when triglycerides are elevated because it captures more atherogenic cholesterol than LDL alone. Many clinicians use non-HDL cholesterol as a secondary target after LDL.
ApoB measures the main protein found on atherogenic particles. Each LDL, VLDL, IDL, remnant particle, and lipoprotein(a) particle carries one ApoB protein, so ApoB acts as a particle count. ApoB can be more informative when LDL-C is low but triglycerides are high, when diabetes or metabolic syndrome is present, or when there is a mismatch between LDL-C and overall risk.
LDL particle number, or LDL-P, is another way to estimate the number of LDL particles. It is often measured through an NMR lipoprotein profile. LDL-P can be helpful in selected cases, but it is not necessary for every person with an LDL result.
Lipoprotein(a), written Lp(a), is a genetically influenced particle that can increase cardiovascular risk even when LDL is well controlled. Most adults only need it measured once because levels are fairly stable over life. A high Lp(a) result does not usually respond much to diet or exercise, but it can support more intensive LDL lowering and tighter control of other risk factors.
Triglycerides help interpret the metabolic setting around LDL. High triglycerides often travel with insulin resistance, fatty liver, type 2 diabetes, increased waist size, and low HDL. When triglycerides are high, calculated LDL may be less reliable, and ApoB or non-HDL cholesterol may better reflect particle-related risk. A separate triglycerides test guide can help explain those ranges and targets.
High-sensitivity C-reactive protein, or hs-CRP, is an inflammation marker sometimes used in cardiovascular risk assessment. It does not replace LDL, but it can identify additional risk in selected people. Blood glucose, A1c, kidney function, blood pressure, and smoking status also shape the LDL target because arteries respond to the combined burden of risk factors.
The most useful LDL interpretation combines the number, the person, and the pattern. LDL-C gives a strong starting point. ApoB, non-HDL cholesterol, triglycerides, Lp(a), coronary calcium, blood pressure, glucose, and family history show whether the LDL target should be more aggressive.
References
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines 2026 (Guideline)
- Guidelines for the Management of Dyslipidemia 2026 (Review)
- 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias 2025 (Guideline)
- 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk 2022 (Expert Consensus)
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice 2021 (Guideline)
- Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials 2024 (Systematic Review)
Disclaimer
LDL cholesterol targets depend on personal cardiovascular risk, medical history, age, pregnancy status, medications, and other blood test results. Do not start, stop, or change cholesterol-lowering medication based only on a single LDL result without guidance from a qualified clinician. Seek urgent medical care for chest pain, sudden shortness of breath, fainting, severe weakness, facial drooping, trouble speaking, or other possible heart attack or stroke symptoms.
